Lysando Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$117K
- Investors
-
1
Lysando General Information
Description
Provider of research and development services intended to overcome the rapidly increasing challenges that originate from pathogenic bacteria. The company offers technological services for the development of products specifically engineered to combat gram-negative and gram-positive bacteria for both antibiotic-resistant and persistent bacteria, enabling clients to apply AI-driven protein design to microbiome-targeted treatments.
Contact Information
Website
www.lysando.comCorporate Office
- Wangerbergstrasse 91
- Triesenberg, 9497
- Liechtenstein
Corporate Office
- Wangerbergstrasse 91
- Triesenberg, 9497
- Liechtenstein
Lysando Timeline
Lysando Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 01-Jan-2026 | $117K | Completed | Generating Revenue | ||
| 2. Secondary Transaction - Private | 01-Aug-2023 | Completed | Generating Revenue | |||
| 1. Corporate | 12-Nov-2014 | Completed | Generating Revenue |
Lysando Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lysando Patents
Lysando Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4150071-A1 | Virus neutralization by soluble receptor fragments of the ace-2 receptor | Inactive | 11-May-2020 | ||
| WO-2021228854-A1 | Virus neutralization by soluble receptor fragments of the ace-2 receptor | Inactive | 11-May-2020 | ||
| US-11958890-B2 | Antimicrobial proteins | Active | 30-May-2018 | ||
| AU-2019276252-A1 | Novel antimicrobial fusion proteins | Inactive | 30-May-2018 | ||
| EP-3802620-A1 | Novel antimicrobial fusion proteins | Inactive | 30-May-2018 | C12N9/2462 |
Lysando Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lysando Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Diana (UK) | Accelerator/Incubator |
Lysando Investments (1)
Lysando’s most recent deal was a PIPE with Amicogen for . The deal was made on 02-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Amicogen | 02-Aug-2021 | PIPE | Biotechnology |
Lysando FAQs
-
When was Lysando founded?
Lysando was founded in 2009.
-
Where is Lysando headquartered?
Lysando is headquartered in Triesenberg, Liechtenstein.
-
What is the size of Lysando?
Lysando has 16 total employees.
-
What industry is Lysando in?
Lysando’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Lysando a private or public company?
Lysando is a Private company.
-
What is Lysando’s current revenue?
The current revenue for Lysando is .
-
How much funding has Lysando raised over time?
Lysando has raised $117K.
-
Who are Lysando’s investors?
Diana (UK) has invested in Lysando.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
